Navigation Links
Treating neonatal meningitis -- is nitric oxide a foe or a friend to bacteria?
Date:2/24/2010

Los Angeles, CA Current research suggests that nitric oxide may play a role in the pathogenesis of neonatal meningitis. The related report by Mittal et al, "Inhibition of inducible nitric oxide controls pathogen load and brain damage by enhancing phagocytosis of Escherichia coli K1 in neonatal meningitis," appears in the March 2010 issue of The American Journal of Pathology.

Bacterial meningitis, or inflammation of the membranes that cover the brain and spinal cord, is often fatal, even when treated with antibiotics. In neonates, mortality occurs in 25 to 35% of all patients, and long-term neurological and psychological effects are reported in up to 50% of survivors. One of the most common causes of neonatal meningitis is a serotype of Escherichia coli that expresses the capsular antigen K1, which is similar in structure to proteins expressed in the brain.

Nitric oxide plays a key role in the pathogenesis of meningitis; however, it remains unclear whether it plays a pro- or anti-microbial role. To determine the role of inducible nitric oxide synthase (iNOS), responsible for the production of nitric oxide, in meningitis, a group led by Dr. Nemani Prasadarao of the Childrens Hospital Los Angeles examined the effects of E. coli K1 infection in brains of neonatal mice. They found that E. coli K1 infection induced nitric oxide due to the activation of iNOS and that mice deficient in iNOS were resistant to E. coli infection. In addition, treatment with the iNOS-specific inhibitor aminoguanidine cleared the pathogen from circulation and prevented brain damage, likely via increased uptake and killing of bacteria by immune cells. Therefore iNOS inhibition may provide a new therapeutic strategy for treating neonatal E. coli-induced meningitis.

Mittal et al conclude that "further understanding of the complex interactions between E. coli K1 and macrophages are important to the identification of novel interventional strategies that can improve the outcome of this deadly disease." Since these studies showed that the prevention of nitric oxide production by E. coli also suppressed the production of inflammatory cytokines, inhibition of nitric oxide might also be used as a therapeutic strategy for the prevention of sepsis. In future studies, Dr. Prasdarao and colleagues intend to "develop small molecule inhibitors that prevent the interaction of E. coli with its receptor on various cells and thereby reduce the production of nitric oxide."


'/>"/>

Contact: Angela Colmone, Ph.D.
acolmone@asip.org
301-634-7953
American Journal of Pathology
Source:Eurekalert

Related biology news :

1. Scripps research team reveals how an old drug could have a new use for treating river blindness
2. Findings show nanomedicine promising for treating spinal cord injuries
3. Research shows treating HIV-AIDS with interleukin-2 is ineffective
4. Treating even mild gestational diabetes reduces birth complications
5. The vasculature emerges as a potential therapeutic target in treating ADPKD liver cysts
6. Treating bone loss in breast cancer survivors
7. Single host gene may hold key to treating both ebola and anthrax infections
8. Test helps in fight against lung infections and for treating other life-threatening infections
9. Glutamine supplements show promise in treating stomach ulcers
10. New hope for advances in treating malaria
11. Cold and brown fat raise the prospect of a new method of treating obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint ... that Rising Market Are you interested in ... forecasts revenues for checkpoint inhibitors. Visiongain,s report gives ... submarket, product and national level. Avoid falling ... what progress, opportunities and revenues those emerging cancer ...
(Date:2/1/2016)... , Feb. 1, 2016  Today, the first day ... announced plans to develop a first of its kind ... of IBM Watson. In the first application of ... (NYSE: IBM ), and Welltok will create a ... assessments with cognitive analytics, delivered on Welltok,s health optimization ...
(Date:1/25/2016)... SEATTLE , Jan. 25, 2016  Glencoe Software, ... biotech, pharma and publication industries, will provide the data ... Phenotypic Screening Centre (NPSC). ... Phenotypic analysis ... even whole organisms, allowing comparisons between states such as ...
Breaking Biology News(10 mins):
(Date:2/9/2016)... ... February 08, 2016 , ... Date ... S. Blumberg Institute at the Pennsylvania Biotechnology Center of Bucks County, 3805 Old ... Commonwealth Medical College (TCMC) will hold an open house for participants to learn ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... The ... the organization’s history, it is offering its 2016 AAT Member Certification Qualification Course for ... The curriculum for the webinar, which will include a detailed review of hardware, software, ...
(Date:2/9/2016)... , Feb. 9, 2016 This market ... the current and future prospects of the market in ... report include companies engaged in the manufacture of microbiology ... executive summary with a market snapshot providing the overall ... of this report. This section also provides the overall ...
(Date:2/9/2016)... 9, 2016 DelveInsight,s, ... report provides in depth insights on the ... the Protein-Tyrosine Phosphatase 1B (PTP1B) Inhibitors. The ... various stages of development including Discovery, Pre-clinical, ... and Preregistration. Report covers the product clinical ...
Breaking Biology Technology: